Core Concepts
Antiviral medication Molnupiravir can lead to mutations in the coronavirus that may spread to other individuals.
Abstract
The study published in Nature highlights the potential impact of Molnupiravir on COVID mutations. Researchers analyzed 15 million COVID genomes, noting increased hallmark mutations linked to the drug in 2022. While no evidence suggests severe variants, scrutiny of Molnupiravir is advised. The antiviral interferes with the virus's replication, but instances of the virus surviving and spreading mutations were observed. The study emphasizes the need for further evaluation by public health officials. Merck questioned the evidence, emphasizing the lack of direct proof of transmission. Molnupiravir was FDA-approved for mild-to-moderate COVID-19 in adults in December 2021, alongside Pfizer's Paxlovid.
Stats
Researchers looked at 15 million COVID genomes.
Molnupiravir increased hallmark mutations in 2022.
FDA authorized Molnupiravir for mild-to-moderate COVID-19 in adults in December 2021.
Quotes
"The signature is very clear, but there aren't any widely circulating variants that have the signature." - Theo Sanderson